# US 2021/0269830 A1 · Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0269830 A1
- Document ID: US20210269830A1
- Status: Published application
- Kind: A1
- Application number: 17/154,309
- Filed: 2021-01-21
- Published: 2021-09-02
- Earliest claimed: 2016-05-18
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Paolo Martini; Stephen Hoge; Kerry Benenato; Vladimir Presnyak; Iain McFadyen; Ellalahewage Sathyajith Kumarasinghe; Ding An; Staci Sabnis
- Web page: https://patentgrep.com/patent/US20210269830A1

## CPC

- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 14/14: Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- G01N 33/6851: {Methods of protein analysis involving laser desorption ionisation mass spectrometry}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- C12Y 207/0701: UTP--hexose-1-phosphate uridylyltransferase (2.7.7.10)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).

## Claims

### Claim at position 1

-160. (canceled)

### Claim 161

A pharmaceutical composition comprising a lipid nanoparticle, wherein the lipid nanoparticle comprises a compound having the Formula (I)
or a salt or stereoisomer thereof, wherein
R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, —R*YR″, —YR″, and —R″M′R′;
R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, C2-14 alkenyl, —R*YR″, —YR″, and —R*OR″, or R2 and R3, together with the atom to which they are attached, form a heterocycle or carbocycle;
R4 is selected from the group consisting of a C3-6 carbocycle, —(CH2)nQ, —(CH2)nCHQR, —CHQR, —CQ(R)2, and unsubstituted C1-6 alkyl, where Q is selected from a carbocycle, heterocycle, —OR, —O(CH2)nN(R)2, —C(O)OR, —OC(O)R, —CX3, —CX2H, —CXH2, —CN, —N(R)2, —C(O)N(R)2, —N(R)C(O)R, —N(R)S(O)2R, —N(R)C(O)N(R)2, —N(R)C(S)N(R)2, —N(R)R8, —O(CH2)nOR, —N(R)C(═NR9)N(R)2, —N(R)C(═CHR9)N(R)2, —OC(O)N(R)2, —N(R)C(O)OR, —N(OR)C(O)R, —N(OR)S(O)2R, —N(OR)C(O)OR, —N(OR)C(O)N(R)2, —N(OR)C(S)N(R)2, —N(OR)C(═NR9)N(R)2, —N(OR)C(═CHR9)N(R)2, —C(═NR9)N(R)2, —C(═NR9)R, —C(O)N(R)OR, and —C(R)N(R)2C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5;
each R5 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R6 is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —N(R′)C(O)—, —C(O)—, —C(S)—, —C(S)S—, —SC(S)—, —CH(OH)—, —P(O)(OR′)O—, —S(O)2—, —S—S—, an aryl group, and a heteroaryl group;
R7 is selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
R8 is selected from the group consisting of C3-6 carbocycle and heterocycle;
R9 is selected from the group consisting of H, CN, NO2, C1-6 alkyl, —OR, —S(O)2R, —S(O)2N(R)2, C2-6 alkenyl, C3-6 carbocycle and heterocycle;
each R is independently selected from the group consisting of C1-3 alkyl, C2-3 alkenyl, and H;
each R′ is independently selected from the group consisting of C1-18 alkyl, C2-18 alkenyl, —R*YR″, —YR″, and H;
each R″ is independently selected from the group consisting of C3-14 alkyl and C3-14 alkenyl;
each R* is independently selected from the group consisting of C1-12 alkyl and C2-12 alkenyl;
each Y is independently a C3-6 carbocycle;
each X is independently selected from the group consisting of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and
provided that when R4 is —(CH2)nQ, —(CH2)nCHQR, —CHQR, or —CQ(R)2, then (i) Q is not —N(R)2 when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2,
wherein the lipid nanoparticle comprises an mRNA that comprises an open reading frame (ORF) encoding a galactose-1-phosphate uridylyltransferase (GALT) polypeptide, wherein the composition is suitable for administration to a human subject in need of treatment for galactosemia type 1 (Gal-1).

### Claim 162 (depends on 161)

The pharmaceutical composition of claim 161, wherein the lipid nanoparticle comprises the compound is of Formula (IA):
or a salt or stereoisomer thereof, wherein
l is selected from 1, 2, 3, 4, and 5;
m is selected from 5, 6, 7, 8, and 9;
M1 is a bond or M′;
R4 is unsubstituted C1-3 alkyl, or —(CH2)nQ, in which Q is OH, —NHC(S)N(R)2, —NHC(O)N(R)2, —N(R)C(O)R, —N(R)S(O)2R, —N(R)R8, —NHC(═NR9)N(R)2, —NHC(═CHR9)N(R)2, —OC(O)N(R)2, —N(R)C(O)OR, heteroaryl or heterocycloalkyl;
M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, —S—S—, an aryl group, and a heteroaryl group; and
R2 and R3 are independently selected from the group consisting of H, C1-14 alkyl, and C2-14 alkenyl.

### Claim 163

A pharmaceutical composition comprising an mRNA comprising an open reading frame (ORF) encoding a galactose-1-phosphate uridylyltransferase (GALT) polypeptide, wherein the composition when administered as a single intravenous dose to a subject in need thereof is sufficient to:
(i) increase the level of GALT activity in RBC and/or liver tissue to within at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% of normal GALT activity level at least 24 hours post-administration, and/or
(ii) increase the level of GALT activity in RBC and/or liver tissue at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 50-fold compared to the subject's baseline GALT activity level or a reference GALT activity level in a subject having galactosemia type 1 (Gal-1) for at least 24 hours post-administration.

### Claim 164

A pharmaceutical composition comprising an mRNA comprising an open reading frame (ORF) encoding a human galactose-1-phosphate uridylyltransferase (GALT) polypeptide, wherein the composition when administered as a single intravenous dose to a subject in need thereof is sufficient to reduce:
(i) RBC and/or liver levels of galactose-1-phosphate (Gal-1-P) at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% compared to the subject's baseline RBC and/or liver Gal-1-P level or a reference RBC and/or liver Gal-1-P level in a subject having galactosemia type 1 (Gal-1) at least 12 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours post-administration, and/or
(ii) plasma, serum, and/or urine levels of galactose at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% compared to the subject's baseline plasma, serum, or urine galactose level or a reference plasma, serum, or urine galactose level in a subject having Gal-1 at least 12 hours, at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours post-administration.

### Claim 165

A pharmaceutical composition comprising an mRNA comprising an open reading frame (ORF) encoding a human galactose-1-phosphate uridylyltransferase (GALT) polypeptide, wherein the composition when administered as a single intravenous dose to a subject in need thereof is sufficient to reduce:
(i) RBC and/or liver levels of galactose-1-phosphate (Gal-1-P) at least 1.5-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 50-fold as compared to the subject's baseline RBC and/or liver Gal-1-P level or a reference RBC and/or liver Gal-1-P level in a patient with galactosemia type 1 (Gal-1), for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours post-administration, and/or
(ii) plasma, serum, and/or urine level of galactose at least 1.5-fold, at least 2-fold at least 5-fold, at least 10-fold, at least 20-fold or at least 50-fold as compared to the subject's baseline plasma, serum, and/or urine galactose level or a reference plasma, serum, and/or urine galactose level in a patient with Gal-1, for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours post-administration.

### Claim 166

An mRNA comprising an open reading frame (ORF) encoding a galactose-1-phosphate uridylyltransferase (GALT) polypeptide, wherein the ORF has at least 85% sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 5 to 29 and 113 to 131.

### Claim 167 (depends on 166)

The mRNA of claim 166, wherein the GALT polypeptide comprises SEQ ID NO:1 or SEQ ID NO:3.

### Claim 168 (depends on 166)

A pharmaceutical composition comprising the mRNA of claim 166 and a delivery agent.

### Claim 169 (depends on 166)

A lipid nanoparticle comprising the mRNA of claim 166.

### Claim 170 (depends on 168)

A method of treating galactosemia type 1 (Gal-1) in a human subject in need thereof, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 168.

### Claim 171 (depends on 169)

A method of treating galactosemia type 1 (Gal-1) in a human subject in need thereof, comprising administering to the human subject an effective amount of the lipid nanoparticle of claim 169.

### Claim 172 (depends on 163)

A method of treating galactosemia type 1 (Gal-1) in a human subject in need thereof, comprising administering to the human subject an effective amount of the pharmaceutical composition of claim 163.

### Claim 173 (depends on 163)

A method of increasing GALT activity in a human subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 163.

### Claim 174 (depends on 173)

The method of claim 173, wherein the level of GALT activity is increased at least 1.5-fold, at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, or at least 50-fold as compared to a reference GALT activity level in a subject having Gal-1 for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, or at least 120 hours post-administration.

### Claim 175 (depends on 164)

A method of reducing a Gal-1-P and/or galactose blood levels in a human subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 164.

### Claim 176 (depends on 175)

The method of claim 175, wherein
(i) the Gal-1-P RBC and/or liver level is reduced at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% as compared to the subject's baseline Gal-1-P RBC and/or liver level or a reference Gal-1-P RBC and/or liver level in a patient with Gal-1, for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, at least 120 hours, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, or 12 days post-administration, and/or
(ii) the galactose plasma, serum, and/or urine level is reduced at least 20%, at least 30%, at least 40%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% as compared to the subject's baseline galactose plasma, serum, and/or urine level or a reference galactose plasma, serum, and/or urine level in a patient with Gal-1, for at least 24 hours, at least 48 hours, at least 72 hours, at least 96 hours, at least 120 hours, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, or 12 days post-administration.
